Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCARTY: Modular CAR T for Myeloma
NCT04795882Phase 1Recruiting
- Sponsor
- University College London
- Start
- Apr 2022
- Primary completion
- Mar 2029
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Allogeneic CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of AUTO8 and D8 chimeric antigen receptor T cells in multiple myeloma (MM) (2 cohorts), sponsored by University College London. Primary endpoints: Incidence of grade 3-5 toxicity causally related to the ATIMP at 28 days and Feasibility of manufacturing CAR T-cells at 30 days. Started Apr 2022; status: recruiting.
02
Drugs
AUTO8D8 chimeric antigen receptor T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04795882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795882.